# US 2010/0135956 A1 · Steroid modulators of progesterone receptor and/or glucocorticoid receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0135956 A1
- Document ID: US20100135956A1
- Status: Published application
- Kind: A1
- Application number: 12/623,593
- Filed: 2009-11-23
- Published: 2010-06-03
- Earliest claimed: 2008-11-21
- Assignees: Auspex Pharmaceuticals, Inc.
- Inventors: Thomas G. Gant; Manouchehr Shahbaz
- Web page: https://patentgrep.com/patent/US20100135956A1

## CPC

- C07J 1/00: Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- A61K 31/569: substituted in position 17 alpha, e.g. ethisterone
- A61K 31/661: Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion {or mevinphos}
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61K 33/243: Platinum; Compounds thereof
- A61K 33/244: Lanthanides; Compounds thereof (medicinal preparations containing radioactive lanthanides for use in therapy or testing in vivo A61K51/00)
- A61K 33/36: Arsenic; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 5/24: of the sex hormones
- A61P 5/30: Oestrogens
- A61P 15/18: Feminine contraceptives
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 35/00: Antineoplastic agents
- C07J: STEROIDS (seco-steroids C07C)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to new steroid modulators of progesterone receptor activity and/or glucocorticoid receptor activity, pharmaceutical compositions thereof, and methods of use thereof.

## Claims

### Claim 1

A compound of structural Formula I
or a salt thereof, wherein:
R1-R32 are independently selected from the group consisting of hydrogen and deuterium;
R33 is selected from the group consisting of —CH3, —CH2D, —CHD2, and —CD3; and
at least one of R1-R33 is deuterium or contains deuterium.

### Claim 2 (depends on 1)

The compound as recited in claim 1 wherein at least one of R1-R33 independently has deuterium enrichment of no less than about 10%.

### Claim 3 (depends on 1)

The compound as recited in claim 1 wherein at least one of R1-R33 independently has deuterium enrichment of no less than about 50%.

### Claim 4 (depends on 1)

The compound as recited in claim 1 wherein at least one of R1-R33 independently has deuterium enrichment of no less than about 90%.

### Claim 5 (depends on 1)

The compound as recited in claim 1 wherein at least one of R1-R33 independently has deuterium enrichment of no less than about 98%.

### Claim 6 (depends on 1)

The compound as recited in claim 1 wherein said compound has a structural formula selected from the group consisting of

### Claim 7 (depends on 1)

The compound as recited in claim 1 wherein said compound has a structural formula selected from the group consisting of

### Claim 8 (depends on 7)

The compound as recited in claim 7 wherein each position represented as D has deuterium enrichment of no less than about 10%.

### Claim 9 (depends on 7)

The compound as recited in claim 7 wherein each position represented as D has deuterium enrichment of no less than about 50%.

### Claim 10 (depends on 7)

The compound as recited in claim 7 wherein each position represented as D has deuterium enrichment of no less than about 90%.

### Claim 11 (depends on 7)

The compound as recited in claim 7 wherein each position represented as D has deuterium enrichment of no less than about 98%.

### Claim 12 (depends on 7)

The compound as recited in claim 7 wherein said compound has the structural formula:

### Claim 13 (depends on 7)

The compound as recited in claim 7 wherein said compound has the structural formula:

### Claim 14 (depends on 7)

The compound as recited in claim 7 wherein said compound has the structural formula:

### Claim 15 (depends on 7)

The compound as recited in claim 7 wherein said compound has the structural formula:

### Claim 16 (depends on 7)

The compound as recited in claim 7 wherein said compound has the structural formula:

### Claim 17 (depends on 7)

The compound as recited in claim 7 wherein said compound has the structural formula:

### Claim 18 (depends on 1)

A pharmaceutical composition comprising a compound as recited in claim 1 together with a pharmaceutically acceptable carrier.

### Claim 19 (depends on 1)

A method of treatment of a progesterone receptor-mediated disorder or a glucocorticoid receptor-mediated disorder comprising the administration of a therapeutically effective amount of a compound as recited in claim 1 to a patient in need thereof.

### Claim 20 (depends on 19)

The method as recited in claim 19 wherein said disorder is selected from the group consisting of non-psychotic major depressive disorder, psychotic disorder, Alzheimer's disease, weight gain, emergency conraception, planned abortion, endometriosis, endometroid carcinoma, breast cancer, Cushing's disease, estrogen deficiency, and glaucoma.

### Claim 21 (depends on 19)

The method as recited in claim 19 further comprising the administration of an additional therapeutic agent.

### Claim 22 (depends on 21)

The method as recited in claim 21 wherein said additional therapeutic agent is misoprostol.

### Claim 23 (depends on 21)

The method as recited in claim 21 wherein said additional therapeutic agent is selected from the group consisting of aromatase inhibitors, selective estrogen receptor modulators, alkylating agents, anti-tumor antibiotic agents, cancer immunotherapy monoclonal antibodies, mitotic inhibitors, tyrosine kinase inhibitors, anti-cancer agents, β2-adrenoreceptor agonists, antimuscarinics, anticholinergics, xanthines, glucocorticoid receptor antagonists, T-cell function modulators, leukotriene receptor antagonists, antihistamines, sympathomimetics, 5-aminosalicylates, immunosuppressants, and prostaglandin analogues.

### Claim 24 (depends on 23)

The method as recited in claim 23 wherein said aromatase inhibitor is selected from the group consisting of anastrozole, aminoglutethimide, letrozole, vorozole, exemestane, formestane, testolactone, and fadrozole.

### Claim 25 (depends on 23)

The method as recited in claim 23 wherein said selective estrogen receptor modulator is selected from the group consisting of afimoxifene, arzoxifene, bazedoxifene, clomifene, femarelle, lasofoxifene, ormeloxifene, raloxifene, tamoxifen, and toremifene.

### Claim 26 (depends on 23)

The method as recited in claim 23 wherein said alkylating agent is selected from the group consisting of chlorambucil, chlormethine, cyclophosphamide, ifosfamide, melphalan, carmustine, fotemustine, lomustine, streptozocin, carboplatin, cisplatin, oxaliplatin, BBR3464, busulfan, dacarbazine, procarbazine, temozolomide, thioTEPA, and uramustine.

### Claim 27 (depends on 23)

The method as recited in claim 23 wherein said anti-tumor antibiotic agent is selected from the group consisting of daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, valrubicin, actinomycin, bleomycin, mitomycin, plicamycin, and hydroxyurea.

### Claim 28 (depends on 23)

The method as recited in claim 23 wherein said cancer immunotherapy monoclonal antibody is selected from the group consisting of rituximab, alemtuzumab, bevacizumab, cetuximab, gemtuzumab, panitumumab, tositumomab, and trastuzumab.

### Claim 29 (depends on 23)

The method as recited in claim 23 wherein said mitotic inhibitor is selected from the group consisting of docetaxel, paclitaxel, vinblastine, vincristine, vindesine, and vinorelbine.

### Claim 30 (depends on 23)

The method as recited in claim 23 wherein said tyrosine kinase inhibitor is selected from the group consisting of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib, and sunitinib.

### Claim 31 (depends on 23)

The method as recited in claim 23 wherein said anti-cancer agent is selected from the group consisting of amsacrine, asparaginase, altretamine, hydroxycarbamide, lonidamine, pentostatin, miltefosine, masoprocol, estramustine, tretinoin, mitoguazone, topotecan, tiazofurine, irinotecan, alitretinoin, mitotane, pegaspargase, bexarotene, arsenic trioxide, denileukin diftitox, bortezomib, and anagrelide.

### Claim 32 (depends on 23)

The method as recited in claim 23 wherein said glucorticoid receptor antagonist is selected from the group consisting of beclometasone, ciclesonide, budesonide, flunisolide, betamethasone, fluticasone, triamcinolone, and mometasone.

### Claim 33 (depends on 23)

The method as recited in claim 23 wherein said leukotriene receptor antagonist is selected from the group consisting of montelukast, pranlukast, and zafirlukast.

### Claim 34 (depends on 23)

The method as recited in claim 23 wherein said antihistamine is selected from the group consisting of bromazine, carbinoxamine, clemastine, chlorphenoxamine, diphenylpyraline, diphenhydramine, doxylamine, brompheniramine, chlorphenamine, dexbrompheniramine, dexchlorpheniramine, dimetindene, pheniramine, talastine, chloropyramine, histapyrrodine, mepyramine, methapyrilene, tripelennamine, alimemazine, hydroxyethylpromethazine, isothipendyl, mequitazine, methdilazine, oxomemazine, promethazine, buclizine, cetirizine, chlorcyclizine, cinnarizine, cyclizine, hydroxyzine, levocetirizine, meclizine, niaprazine, oxatomide, antazoline, azatadine, bamipine, cyproheptadine, deptropine, dimebon, ebastine, epinastine, ketotifen, mebhydrolin, mizolastine, phenindamine, pimethixene, pyrrobutamine, rupatadine, triprolidine, acrivastine, astemizole, azelastine, desloratadine, fexofenadine, loratadine, terfenadine, antazoline, azelastine, emedastine, epinastine, ketotifen, olopatadine, cromylin sodium and theophylline.

### Claim 35 (depends on 23)

The method as recited in claim 23 wherein said xanthine is selected from the group consisting of diprophylline, choline theophyllinate, proxyphylline, theophylline, aminophylline, etamiphylline, paraxanthine, caffeine, theobromine, bamifylline, acefylline piperazine, bufylline, and doxofylline.

### Claim 36 (depends on 23)

The method as recited in claim 23 wherein said sympathomimetic is selected from the group consisting of cyclopentamine, ephedrine, phenylephrine, oxymetazoline, tetryzoline, xylometazoline, naphazoline, tramazoline, metizoline, tuaminoheptane, fenoxazoline, tymazoline, epinephrine, phenylpropanolamine, and pseudoephedrine.

### Claim 37 (depends on 23)

The method as recited in claim 23 wherein said anticholinergic is selected from the group consisting of oxyphencyclimine, camylofin, mebeverine, trimebutine, rociverine, dicycloverine, dihexyverine, difemerine, piperidolate, benzilone, glycopyrronium, oxyphenonium, penthienate, propantheline, otilonium bromide, methantheline, tridihexethyl, isopropamide, hexocyclium, poldine, mepenzolate, bevonium, pipenzolate, biphemanil, (2-benzhydryloxyethyl)diethyl-methylammonium iodide, tiemonium iodide, prifinium bromide, timepidium bromide, ipratropium bromide, and fenpiverinium.

### Claim 38 (depends on 23)

The method as recited in claim 23 wherein said β2-adrenoreceptor agonist is selected from the group consisting of salbutamol, levosalbutamol, terbutaline, pirbuterol, procaterol, metaproterenol, fenoterol, bitolterol mesylate, reproterol, salmeterol, formoterol, bambuterol, clenbuterol, and indacaterol.

### Claim 39 (depends on 19)

The method as recited in claim 19, further resulting in at least one effect selected from the group consisting of:
a. decreased inter-individual variation in plasma levels of said compound or a metabolite thereof as compared to the non-isotopically enriched compound;
b. increased average plasma levels of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;
c. decreased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;
d. increased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound; and
e. an improved clinical effect during the treatment in said subject per dosage unit thereof as compared to the non-isotopically enriched compound.

### Claim 40 (depends on 19)

The method as recited in claim 19, further resulting in at least two effects selected from the group consisting of:
a. decreased inter-individual variation in plasma levels of said compound or a metabolite thereof as compared to the non-isotopically enriched compound;
b. increased average plasma levels of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;
c. decreased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound;
d. increased average plasma levels of at least one metabolite of said compound per dosage unit thereof as compared to the non-isotopically enriched compound; and
e. an improved clinical effect during the treatment in said subject per dosage unit thereof as compared to the non-isotopically enriched compound.

### Claim 41 (depends on 19)

The method as recited in claim 19, wherein the method effects a decreased metabolism of the compound per dosage unit thereof by at least one polymorphically-expressed cytochrome P450 isoform in the subject, as compared to the corresponding non-isotopically enriched compound.

### Claim 42 (depends on 41)

The method as recited in claim 41, wherein the cytochrome P450 isoform is selected from the group consisting of CYP2C8, CYP2C9, CYP2C19, and CYP2D6.

### Claim 43 (depends on 19)

The method as recited claim 19, wherein said compound is characterized by decreased inhibition of at least one cytochrome P450 or monoamine oxidase isoform in said subject per dosage unit thereof as compared to the non-isotopically enriched compound.

### Claim 44 (depends on 43)

The method as recited in claim 43, wherein said cytochrome P450 or monoamine oxidase isoform is selected from the group consisting of CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2A13, CYP2B6, CYP2C8, CYP2C9, CYP2C18, CYP2C19, CYP2D6, CYP2E1, CYP2G1, CYP2J2, CYP2R1, CYP2S1, CYP3A4, CYP3A5, CYP3A5P1, CYP3A5P2, CYP3A7, CYP4A11, CYP4B1, CYP4F2, CYP4F3, CYP4F8, CYP4F11, CYP4F12, CYP4X1, CYP4Z1, CYP5A1, CYP7A1, CYP7B1, CYP8A1, CYP8B1, CYP11A1, CYP11B1, CYP11B2, CYP17, CYP19, CYP21, CYP24, CYP26A1, CYP26B1, CYP27A1, CYP27B1, CYP39, CYP46, CYP51, MAOA, and MAOB.

### Claim 45 (depends on 19)

The method as recited in claim 19, wherein the method reduces a deleterious change in a diagnostic hepatobiliary function endpoint, as compared to the corresponding non-isotopically enriched compound.

### Claim 46 (depends on 45)

The method as recited in claim 45, wherein the diagnostic hepatobiliary function endpoint is selected from the group consisting of alanine aminotransferase (“ALT”), serum glutamic-pyruvic transaminase (“SGPT”), aspartate aminotransferase (“AST,” “SGOT”), ALT/AST ratios, serum aldolase, alkaline phosphatase (“ALP”), ammonia levels, bilirubin, gamma-glutamyl transpeptidase (“GGTP,” “γ-GTP,” “GGT”), leucine aminopeptidase (“LAP”), liver biopsy, liver ultrasonography, liver nuclear scan, 5′-nucleotidase, and blood protein.

### Claim 47 (depends on 1)

A compound as recited in claim 1 for use as a medicament.

### Claim 48 (depends on 1)

A compound as recited in claim 1 for use in the manufacture of a medicament for the prevention or treatment of a disorder ameliorated by modulating progesterone receptor activity or glucocorticoid receptor activity.
